Next Article in Journal
The Search for Natural Inhibitors of Biofilm Formation and the Activity of the Autoinductor C6-AHL in Klebsiella pneumoniae ATCC 13884
Previous Article in Journal
Non-Toxic and Ultra-Small Biosilver Nanoclusters Trigger Apoptotic Cell Death in Fluconazole-Resistant Candida albicans via Ras Signaling
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Biomolecules 2019, 9(2), 48;

A Biophysical Approach to the Identification of Novel ApoE Chemical Probes

Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Chichester II, Falmer, Brighton BN1 9QJ, UK
Dementia Research Group, Sussex Neuroscience, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QJ, UK
Medicines Discovery Institute, Cardiff University, Park Place, Cardiff CF10 3AT, UK
Author to whom correspondence should be addressed.
Received: 30 November 2018 / Revised: 23 January 2019 / Accepted: 24 January 2019 / Published: 29 January 2019
Full-Text   |   PDF [3161 KB, uploaded 29 January 2019]   |  
  |   Review Reports


Alzheimer’s disease (AD) is the most common type of dementia and, after age, the greatest risk factor for developing AD is the allelic variation of apolipoprotein E (ApoE), with homozygote carriers of the ApoE4 allele having an up to 12-fold greater risk of developing AD than noncarriers. Apolipoprotein E exists as three isoforms that differ in only two amino acid sites, ApoE2 (Cys112/Cys158), ApoE3 (Cys112/Arg158), and ApoE4 (Arg112/Arg158). These amino acid substitutions are assumed to alter ApoE structure and function, and be responsible for the detrimental effects of ApoE4 via a mechanism that remains unclear. The hypothesis that a structural difference between ApoE4 and ApoE3 (and ApoE2) is the cause of the ApoE4-associated increased risk for AD forms the basis of a therapeutic approach to modulate ApoE4 structure, and we were therefore interested in screening to identify new chemical probes for ApoE4. In this regard, a high-yield protocol was developed for the expression and purification of recombinant full-length ApoE, and three diverse biophysical screening assays were established and characterized; an optical label-free assay (Corning Epic) for hit identification and microscale thermophoresis (MST) and isothermal titration calorimetry (ITC) as orthogonal assays for hit confirmation. The 707 compounds in the National Institute of Health clinical collection were screened for binding to ApoE4, from which six confirmed hits, as well as one analogue, were identified. Although the compounds did not differentiate between ApoE isoforms, these data nevertheless demonstrate the feasibility of using a biophysical approach to identifying compounds that bind to ApoE and that, with further optimization, might differentiate between isoforms to produce a molecule that selectively alters the function of ApoE4. View Full-Text
Keywords: ApoE; Alzheimer’s disease; drug discovery; high-throughput screening; chemical probes; biophysical assays ApoE; Alzheimer’s disease; drug discovery; high-throughput screening; chemical probes; biophysical assays

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Kraft, L.; Serpell, L.C.; Atack, J.R. A Biophysical Approach to the Identification of Novel ApoE Chemical Probes. Biomolecules 2019, 9, 48.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top